PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30526541-0	2018	Activation of LXRalpha/beta by cholesterol in malignant ascites promotes chemoresistance in ovarian cancer.	Cholesterol	31-42	nuclear receptor subfamily 1 group H member 3	Homo sapiens	14-22	
30526541-7	2018	RESULTS: Here we show that cholesterol is elevated in malignant ascites and modulates the sensitivity of ovarian cancer cells to CDDP and PAC by upregulating the expression of drug efflux pump proteins, ABCG2 and MDR1, together with upregulation of LXRalpha/beta, the cholesterol receptor.	Cholesterol	27-38	nuclear receptor subfamily 1 group H member 3	Homo sapiens	249-257	
30526541-8	2018	Transfection of LXRalpha/beta siRNA inhibited cholesterol-induced chemoresistance and upregulation of MDR1.	Cholesterol	46-57	nuclear receptor subfamily 1 group H member 3	Homo sapiens	16-24	
30526541-10	2018	Cholesterol depletion by methyl beta cyclodextrin (MbetaCD) inhibited malignant ascites-induced chemoresistance to CDDP and upregulation of MDR1 and LXRalpha/beta.	Cholesterol	0-11	nuclear receptor subfamily 1 group H member 3	Homo sapiens	149-157	
30526541-12	2018	CONCLUSIONS: High cholesterol in malignant ascites contributes to poor prognosis in ovarian cancer patients, partly by contributing to multidrug resistance through upregulation of MDR1 via activation of LXRalpha/beta.	Cholesterol	18-29	nuclear receptor subfamily 1 group H member 3	Homo sapiens	203-211